Literature DB >> 19157501

Pediatric sinonasal neuroendocrine carcinoma after treatment of retinoblastoma.

Alessandro Franchi1, Iacopo Sardi, Valentina Cetica, Annamaria Buccoliero, Flavio Giordano, Federico Mussa, Lorenzo Genitori, Giuseppe Oliveri, Clelia Miracco.   

Abstract

Patients who survive retinoblastoma are at risk for developing additional malignant neoplasms, including tumors of the sinonasal tract. We report 2 cases of secondary sinonasal malignancy arising in pediatric patients previously treated for retinoblastoma, with features of neuroendocrine carcinoma. Both lesions were characterized by a proliferation of round to oval cells arranged in solid sheets, trabeculae, and nests, diffusely infiltrating nasal mucosa and bone tissue. Immunohistochemically, they were diffusely positive for epithelial markers, as well as for neuroendocrine markers and for TP53 and retinoblastoma gene products. TP53 gene analysis showed the presence of a missense mutation P72R (CCC/CGC) and a single nucleotide polymorphism P36P (CCG/CCA) in exon 4 in 1 case. Literature review revealed 5 previously reported cases, all showing primitive undifferentiated morphology with variable expression of neural and epithelial markers. These tumors represent a peculiar subset of undifferentiated sinonasal neoplasms with extremely aggressive clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19157501     DOI: 10.1016/j.humpath.2008.09.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto's thyroiditis.

Authors:  R M Ruggeri; T M Vicchio; S Giovinazzo; R Certo; A Alibrandi; F Trimarchi; S Benvenga; M Trovato
Journal:  J Endocrinol Invest       Date:  2015-05-03       Impact factor: 4.256

2.  Sinonasal adenocarcinoma: a rare second malignancy in long term retinoblastoma survivors.

Authors:  Pooja Bhagia; Agnes Basas Colanta; David H Abramson; Diane L Carlson; Ruth A Kleinerman; Dennis Kraus; Ira J Dunkel
Journal:  Pediatr Blood Cancer       Date:  2011-05-05       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.